Valuation: Neurocrine Biosciences, Inc.

Market Cap 16.48B 15.02B 13.9B 12.58B 23.59B 1,540B 24.69B 168B 66.66B 832B 61.84B 60.55B 2,635B P/E 2026 *
21.4x
P/E 2027 * 16x
Enterprise Value 14.81B 13.49B 12.49B 11.3B 21.2B 1,383B 22.19B 151B 59.9B 747B 55.57B 54.4B 2,368B EV / Sales 2026 *
3.71x
EV / Sales 2027 * 2.94x
Free-Float
98.92%
Yield 2026 *
-
Yield 2027 * -
1 day-3.85%
1 week-10.22%
Current month+7.18%
1 month+15.39%
3 months+1.53%
6 months-0.39%
Current year+10.41%
1 week 156.31
Extreme 156.31
171.16
1 month 137.9
Extreme 137.9
174.59
Current year 122.14
Extreme 122.1375
186.12
1 year 122.14
Extreme 122.1375
186.12
3 years 84.23
Extreme 84.23
186.12
5 years 71.88
Extreme 71.875
186.12
10 years 37.34
Extreme 37.345
186.12
Manager TitleAgeSince
Chief Executive Officer 53 11/10/2024
Director of Finance/CFO 46 01/11/2017
Chief Tech/Sci/R&D Officer 62 08/01/2018
Director TitleAgeSince
Director/Board Member 68 01/01/2008
Director/Board Member 64 01/04/1998
Chairman 78 01/05/2011
Date Insider Type Main position Quantity % Market Cap. Importance
04/11/26 Free

Chief Technology Officer

9,820 0.0097%
03/11/26 Exercice

Director

21,600 0.0212%
01/11/26 Exercice

Chief Executive Officer

1,560 0.0015%
Change 5-day change 1-year change 3-year change Capi.($)
-3.85%-10.22%+12.96%+43.74% 16.48B
-2.29%-6.00%+31.17%+128.34% 1,232B
-2.04%-4.73%+33.57%+78.34% 656B
-0.86%-3.88%+21.24%+105.02% 506B
-1.04%-0.67%+30.16%+68.01% 382B
-3.61%-9.76%+37.73%+30.53% 340B
-3.22%-4.14%+24.75%+51.30% 294B
-2.51%-4.26%-1.93%+29.67% 278B
-1.14%-6.26%+27.57%+65.35% 240B
-1.45%-1.89%+30.94%+120.72% 210B
Average -1.94%-2.74%+24.81%+72.10% 415B
Weighted average by Cap. -1.42%-2.69%+27.82%+87.63%

Financials

2026 *2027 *
Net sales 3.99B 3.64B 3.37B 3.05B 5.72B 373B 5.98B 40.72B 16.15B 202B 14.98B 14.67B 638B 4.58B 4.18B 3.87B 3.5B 6.56B 428B 6.86B 46.72B 18.53B 231B 17.19B 16.83B 733B
Net income 783M 713M 660M 597M 1.12B 73.11B 1.17B 7.98B 3.17B 39.51B 2.94B 2.88B 125B 1.04B 950M 880M 796M 1.49B 97.42B 1.56B 10.63B 4.22B 52.64B 3.91B 3.83B 167B
Net Debt -1.67B -1.52B -1.41B -1.28B -2.39B -156B -2.51B -17.06B -6.77B -84.45B -6.28B -6.15B -268B -3B -2.73B -2.53B -2.29B -4.29B -280B -4.49B -30.58B -12.13B -151B -11.25B -11.02B -480B
Projected Income Statement - Annual - Neurocrine Biosciences, Inc.
Logo Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). It also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampator॥ / (AMPA PAM) and others.
Employees
2,500
Date Price Change Volume
19/11/26 $156.59 -3.85% 1,350,819
18/11/26 $162.86 -1.84% 1,600,790
17/11/26 $165.92 +0.37% 1,142,354
16/11/26 $165.31 -1.25% 1,386,045
13/11/26 $167.40 -1.18% 1,380,856
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Neurocrine Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
156.59USD
Average target price
208.54USD
Spread / Average Target
+33.18%
  1. Stock Market
  2. Stocks
  3. NBIX Stock